The f3-adrenergic antagonist propranolol has been found to inhibit platelet aggregation.
reported with the 4-hydroxy metabolite of propranolol.' Prostacyclin (prostaglandin [PG] 12) is a potent vasodilator and inhibitor of platelet aggregation. 9 The vessel wall appears to be a primary site of PGI2 synthesis, with the intimal surface generating greater amounts than that formed by cells closer to the adventitia.'0 Numerous investigators have demonstrated that the vascular endothelium synthesizes PGI2. Since the vascular endothelium is in direct contact with platelets circulating in the blood, the stimulation of PGL2 synthesis from this tissue by pharmacologic agents could produce an antiplatelet effect. The intent of the current investigation was to determine whether propranolol exerts a portion of its antiplatelet activity by increasing the synthesis or affecting the activity of PGI2. Consequently, the effect of propranolol on PGI2 synthesis was studied in cultured human endothelial cells. Additionally, the effects of propranolol on platelet aggregation, platelet cyclic AMP production, and Vol. 17, No. 6, June 1985 Tx synthesis were investigated in the presence and absence of PGI2.
Methods
Materials. Drugs used and their sources were as follows: dlpropranolol (Ayerst), d-propranolol (Ayerst), thrombin (Parke-Davis), arachidonic acid (Sigma), adenosine-3,5-cyclic monophosphate (Sigma), monosuccinyl adenosine-3 ,5 '-cyclic monophosphoric acid tyrosine methyl ester (Sigma), isobutylmethylxanthine (Aldrich), 2',5'-dideoxyadenosine (P.L. Biochemicals, Inc.,), TxB2 (Upjohn), PGI2 (Upjohn), PGE2 (Upjohn), 3H-6-keto-PGFI, (Amersham), 3H-PGE2 (Amersham), and 3H-TxB2 (New England Nuclear).
All of the solvents used for assays were of reagent grade and were purified by fractional distillation before use.
Endothelial cell culture. Endothelial cells were cultured from vessels of human lungs or umbilical cords as previously described. 16, 17 Briefly, the vessels were perfused with 0.2% collagenase in cell culture medium (medium 199. Gibco), then the ends of the vessels were clamped while the solution remained in the lumen for 15 min at 370 C. The detached cells were rinsed from the vessels with fresh culture medium, washed twice, and resuspended in culture medium supplemented with antibiotics, fetal calf serum, and human serum. The cells were plated in 25 cm2 flasks and kept in an incubator at 370 C in an atmosphere of 5% CO2 and 95% air. Umbilical cord cells were used without passage, but pulmonary cells had to be transferred at least once to obtain sufficient material for experiments.
Prostacyclin bioassay experiments. Supematant media from the cultured endothelial cell monolayer were tested for PGI2 production by bioassay on platelet aggregation in vitro. The cell monolayers were washed twice in protein-free culture medium and fresh medium with or without propranolol added. The cells were incubated for 15 min at 370 C, and the supernatant was collected into 10 mM Na2CO3 (pH 9.2), kept on ice, and tested within 1 hr for effects on platelet aggregation. These precautions were taken to minimize breakdown of PGIL into its inactive metabolite, 6-keto-PGFI,.
Prostaglandin synthesis from endothelial cultures. For quantitative determination of 6-keto-PGFi, and PGE2, individual flasks of cells were incubated for 15 min at 37°C with medium alone, medium with thrombin (5.0 U/ml), or medium with varying amounts of dl-propranolol. The medium was removed from the cells, acidified with glacial acetic acid to pH 3.0, and extracted with 10 x volume of ethyl acetate:cyclohexane (1:1) and the organic phase was dried under nitrogen. This extract was reconstituted to the original volume in phosphatebuffered saline (pH 7.4) containing polyvinylpyrrolidone (0.1%). The PGs were measured by radioimmunoassay (see below) in duplicate aliquots from each sample. Platelet experiments in vitro. Blood was obtained by venipuncture from normal subjects who had taken no drugs for at least 10 days before the study. The blood was diluted in onetenth volume of 3.5% sodium citrate, pH 7.4. Platelet rich plasma (PRP) was prepared by centrifuging the blood at 150 g for 10 min. After removal of the PRP, the remaining red cell suspension was centrifuged at 1500 g for 10 min to obtain platelet-poor plasma (PPP). This PPP was used to standardize the aggregometer and to dilute the PRP. The platelet count in the PRP averaged 200 + 10 x 103 platelets/ml.
The PRP was kept in a tightly closed plastic container at room temperature, and experiments were completed within 3 hr of collection of blood. Platelet aggregation was monitored in vitro by the method of Born'8 using a dual-channel Sienco aggregometer. One milliliter of PRP was incubated at 370 C with constant stirring at 1000 rpm. Propranolol or its vehicle (phosphate-buffered saline) was incubated with the platelets for 2 min before the addition of the aggregating agent. PGI2 was added 30 sec before the addition of the aggregating agent. Aggregation was stimulated by either thrombin (0.5 U/ml) or arachidonic acid (3 x 10-4M). PGI2 was diluted in 50 mM Tris buffer, pH 9.4, kept on ice, and used within 2 hr of preparation. Arachidonic acid was dissolved in hexane and dried in the cuvette under nitrogen before addition of PRP.
For radioimmunoassay of TxB2, PRP was sampled before the addition of the aggregating agent and at various times after addition of the aggregating substance. A 50 ,ul aliquot of PRP was removed from the cuvette, immediately added to 450 g.l of ice-cold phosphate-buffered saline or distilled water containing indomethacin (1 .g/ml), and quick-frozen in a methanol-dry ice bath. These samples were kept frozen at -200 C until assay. For measurement of cyclic AMP (see below), samples were obtained by incubating 1.0 ml of PRP containing 100 p.M isobutylmethylxanthine with the test drug(s) and the aggregating agent. The reaction was terminated after 1 min by transferring the platelets to a polypropylene tube containing 0.8 ml of 5% trichloroacetic acid (TCA) and freezing the samples immediately in liquid nitrogen. The samples were kept frozen at -200 C until assay.
Radioimmunoassay for prostanoids. Synthesis of PGs by platelets and endothelial cells was measured by specific radioimmunoassays according to the method of Dray et al.19 as modified by Campbell et al.20 Specific antibodies were raised in rabbits against a PG-thyroglobulin complex. The TxB2 antibody detected amounts as low as 1 pg/0.3 ml and cross-reacted less than 0.001% with PGA2, PGB2, PGE2, PGF2a, and 6-keto-PGFIa, and less than 0.003% with PGD2. The PGE2 antibody detected 10 pg/0.3 ml and cross-reacted less than 0.7% with PGA2, PGB2, PGD2, 1 5-keto-PGE2, 13,14-dihydro-15-keto-PGE2, PGF2,, PGFIa, and 6-keto-PGF,,. It cross-reacted 14.0% with PGE,. The 6-keto-PGFI, antibody was able to detect 5 pg/0.3 ml, and cross-reacted 14% with PGFIa, 2% with PGEI, and less than 0.6% with other known PGs and 6-keto-PGFI,, metabolites.
The radioimmunoassay consisted of combining 0.1 ml of the diluted sample with 0.1 ml of 3H-PG and 0.1 ml of specific antiserum in a 12 x 75 mm polypropylene culture tube. After overnight incubation at 40 C, the antibody-bound and free PGs were separated with dextran-coated charcoal. The bound radioactivity was counted in liquid scintillation spectrometer.
Cyclic AMP radioimmunoassay. Platelet samples were obtained as described above. The frozen samples were thawed on ice and homogenized for 30 sec with a Brinkman Polytron. The protein precipitate was removed by centrifugation at 5000 g for 30 min at 40 C. The supernatants were extracted four times with a 10-fold excess of water-saturated diethyl ether to remove the TCA. Residual ether was removed under a stream of nitrogen for 30 min. An aliquot of the sample was then assayed for cyclic AMP.
Platelet cyclic AMP levels were measured by radioimmuno- The cyclic AMP assay consisted of combining 50 ,ul of acetylated standard or sample, 50 p.1 of 50 mM sodium acetate buffer, 100 p.1 of the antibody solution, and 100 p.l of 1251-cyclic AMP (10,000 cpm) in a 12 x 75 mm glass tube. The antiserum for the cyclic AMP was used in a final dilution of 1:100,000. After an incubation at 40 C for 3 hr or overnight, the antibody-bound and free cyclic AMP were separated by the addition of charcoal. The bound radioactivity was counted with a Packard gamma scintillation spectrometer. The assay was sensitive to 50 fmol/0.3 ml.
Statistical analysis. Tx and cyclic AMP generation in the platelet experiments were evaluated by analysis of variance with the Neuman-Keuls multiple comparisons test. In aggregation experiments, when percent of maximal responses were compared, a Mann-Whitney U test was used since percentages do not follow a normal distribution.
Results
The release of PGI2 from cultured endothelial cells could be shown by the ability of the incubation media to inhibit aggregation in PRP (figure 1). Thrombin was used to stimulate aggregation. The addition of a small volume (10 ,ul) of the media from vehicle-treated cells resulted in a slight diminution of the aggregatory response. The inhibition of aggregation was increased when a greater volume of media from the control flask was added to the PRP (data not shown). Media not exposed to cells had no inhibitory effect on platelet aggregation (data not shown). Ten microliters of media that contained dl-propranolol (10-6M), but was not exposed to the cultured cells, caused only a small de- figure 1 . In contrast, media from cells incubated with either dl-or d-propranolol (10-6M) caused marked attenuation of aggregation. When the results from several experiments were combined, propranolol-treated cultures were found to consistently have two to three times more inhibitory activity than medium from vehicle-treated cultures. Thus, propranolol treatment enhanced the antiaggregatory activity of media from endothelial cells, whereas the same concentration of propranolol added alone was not inhibitory. The results suggest that propranolol stimulated release of PGI2 from endothelial cells.
To further test this possibility, the release of PGI2 from cultured endothelial cells was measured by radioimmunoassay as its stable metabolite, 6-keto-PGFI. Table 1 shows the results obtained in pulmonary endothelial cells. While both arterial and venous cells produced PGI2, the venous cells synthesized more 6-keto-PGFia than did the arterial cells. Propranolol did not change basal synthesis at any dose tested. Umbilical venous endothelium was also tested. The basal and thrombin-stimulated production of 6-keto-PGFia and PGE2 is shown in keto-PGFIa were considerably higher than those of PGE2. The synthesis of both PGs was stimulated by thrombin treatment, but PGE2 synthesis was enhanced to a greater extent than 6-keto-PGFia synthesis. Incubation with varying amounts of dl-propranolol for 30 min had no effect on either the basal or thrombinstimulated generation of either PGE2 or 6-keto-PGF a Identical results were obtained in endothelial cells incubated for 3 to 5 days with the drug (data not shown).
These results suggest that instead of increasing the production of PGL2, propranolol instead may amplify the inhibitory activity of PGI2. To test this hypothesis, the effects of dl-and d-propranolol on the antiaggrega- (51%). The inclusion of dl-propranolol enhanced the antiaggregatory effect of PGI2 at all concentrations tested. This enhanced effect was also observed with dpropranolol, as shown in the far right portion of figure 2. Thus, propranolol had a greater than additive effect in reducing platelet aggregability in vitro when used in combination with PGI2, and this was most pronounced at low concentrations of PGJ2. Figure 3 illustrates the effects of propranolol and PGI2 on TxA2 generation by platelets. Thrombin stimulated the production of TxB2, which reached a maximum of 28.3 ng/ml of PRP. Platelets incubated with 1.25 nM PGI2 produced a markedly decreased amount of TxB2 (7.8 ng/ml), as did those incubated with 10 -7M dl-propranolol (4.4 ng/ml). The TxB2 production in the presence of both PGI2 and propranolol (3.3 ng/ml) did not differ significantly from the levels measured in platelets incubated with either agent alone. However, in examining the aggregatory responses in these experiments, it was apparent that the effects of propranolol and PGI2 were additive. Propranolol and PGI2 alone attenuated aggregation by 29% and 56%, respectively, but the combination reduced aggregation by 73%.
The inhibition of platelet aggregation by PGI2 is thought to be related to increases of cyclic AMP. 24 25 We observed that the attenuation of TxB2 formation by PGJ2 also correlated with increases in cyclic AMP (figure 4 ). There was a slight, but not statistically significant, increase in cyclic AMP levels with 1.25 nM PGI2 from a basal value of 7.6 pmol/ml PRP to 8.5 pmol/ml PRP. However, at this concentration of PGI2 there was significant inhibition of aggregation (60%) and TxB2 synthesis (50%). With 2.5 nM PGI2, cyclic AMP levels increased to 13.7 pmol/ml (p < .01) , and aggregation and TxB2 formation were reduced by 94% and 88%, respectively. At higher concentrations, PGI2 stimulated further increments in cyclic AMP synthesis while both aggregation and TxB2 production were completely inhibited.
2',5'-Dideoxyadenosine (DDA) is a potent inhibitor of platelet adenylate cyclase in both intact cells and membrane preparations.25 When DDA alone (100 gM) was incubated with PRP, there was no effect on the aggregatory response to either thrombin or arachidonic acid (figures 5 and 6). PGI2 (2.5 nM) significantly inhibited the synthesis of TxB2 and aggregation in platelets stimulated with thrombin (figure 5) or arachidonic acid ( figure 6 ). When the inhibitory effect of propranolol, platelets were incubated with DDA and/or propranolol (figure 7) . DDA alone had no effect on either response. Propranolol (10-6M) completely inhibited aggregation and attenuated the generation of TxB2 by 55% (p < .05). In contrast to the studies with PGI2, pretreatment of the platelets with DDA did not alter the inhibitory actions of propranolol on either aggregation or TxB2 synthesis.
When cyclic AMP levels were measured, PG12 (2.5 nM) significantly increased cyclic AMP and significantly inhibited aggregation (table 3) . Pretreatment of PRP with DDA blocked the PGI2-induced increase in cyclic AMP as well as its ability to inhibit platelet 1242 aggregation. dl-Propranolol (10 -6M) did not change the mean cyclic AMP level from the control value (8.6 pmol/ml for control vs 9.5 pmol/ml with propranolol). However, propranolol did significantly inhibit platelet aggregation (53%). When the effect of propranolol was tested over a wide range of concentrations (from 10-8 to 10-5M) there was no change from control in the amount of cyclic AMP produced even when aggregation was completely inhibited (data not shown). Finally, the cyclic AMP levels in platelets treated with both dl-propranolol and PG12 were significantly increased (16.9 pmol/ml) over control, but were not different from the values obtained with PGI1 alone. Thus, propranolol alone did not increase the generation of cyclic AMP, nor did it affect PGI stimulation of cyclic AMP synthesis.
Discussion
Propranolol has been found to inhibit platelet aggregation by some unidentified mechanism.' -Since the vascular endothelium synthesizes PGI2, a potent endogenous inhibitor of platelet aggregation,9 the current investigation was undertaken to examine if propranolol exerts its antiplatelet activity by stimulating the synthesis of PG!2 by cultured human endothelial cells. Additionally, we investigated the effects of the combination of PGI, and propranolol on platelet aggregation and TxB, synthesis and the effects of these agents on platelet cyclic AMP accumulation.
The media from cultures of human endothelial cells have been found to inhibit platelet aggregation and to contain PGI1. 146 This antiaggregatory activity has been attributed to PGI, since this activity is abolished by heating to 1000 C, acidification to pH 4, cyclooxygenase inhibitors, or the prostacyclin-synthetase inhibitor tranylcypromine. When endothelial cells were incubated with propranolol, the inhibitory activity of the culture media was greater than that observed in media from untreated cultures. This result suggested that propranolol treatment inhibited aggregation by stimulating the synthesis of PG12 in the endothelial cells. However, when PG12 synthesis was determined by radioimmunoassay of 6-keto-PGF0, propranolol did not change either basal or thrombin-stimulated PG12 synthesis over a wide range of concentrations. There was also no effect of propranolol on PGE2 generation. Thus, the antiaggregatory effects of propranolol did not appear to be due to increased prostanoid synthesis in these cultured cells.
Rigas and Levine-2 examined the effect of propranolol on arachidonic acid metabolism by studying various types of cultured cells, but endothelial cells were not studied. Their results showed that propranolol stimulated PG synthesis (i.e., PGE2, PGF,, and 6keto-PGF,,) in cultured cells of dog kidney, rat basophil leukemia, mouse adrenal, and mouse neuroblastoma, but not in bovine aortic smooth muscle or rat glioma cells. Consequently, they suggested that the renin-independent antihypertensive action of propranolol might be due to increased synthesis of PG1. The difference in propranolol's efficacy in stimulating PGI2 generation in the present study compared with that of Rigas and Levine may be attributable to the different cell types that were examined. Additionally, the concentrations used by Rigas and Levine (2 x 10'4M) were considerably higher than those used in our study.
If propranolol does not stimulate PGI, synthesis, inhibited arachidonic acid-induced aggregation while causing only small increases in the platelet cyclic AMP formation. These findings suggest that the inhibition of platelet aggregation and TxB2 formation is dependent on cyclic AMP at high concentrations of PGI2 (>2.5 nM), but is independent of cyclic AMP at low concentrations (<2.5 nM). Alternatively, cyclic AMP may mediate the effects of PG12 at all concentrations, but total platelet cyclic AMP content may inadequately access the accumulation of the nucleotide at regulatory sites in the cell. Results of studies with DDA, a potent inhibitor of adenylate cyclase,27 also support a role for cyclic AMP in the antiaggregatory activity of PGI2 at higher concentrations. When given alone, DDA did not alter basal cyclic AMP levels, Tx synthesis, or platelet aggregation. However, DDA blocked the ability of PGC2 to inhibit arachidonic acid or thrombin stimulation of aggregation. Similar findings were reported by Haslam et al. 28 Additionally, DDA blocked the increase in cyclic AMP and decrease in TxB2 caused by PGI2 treatment. These results support the hypothesis that the inhibitory effect of PGI2 on platelet aggregation is cyclic AMP dependent. The role of cyclic AMP in the antiaggregatory activity of propranolol was investigated in a manner similar to that in the PGI2 studies. Propranolol inhibited TxB2 synthesis and platelet aggregation, but DDA did not reverse these effects of propranolol as it did with PGI2. In agreement with this finding, propranolol in concentrations that attenuate aggregation and Tx formation failed to increase cyclic AMP levels from control values. Furthermore, the ability of PGI2 to increase the production of cyclic AMP was not enhanced by propranolol even though the aggregatory response was enhanced. These observations support the conclusion that the antiaggregatory action of propranolol is independent of cyclic AMP synthesis. The exact mechanism by which propranolol inhibits platelet aggregation and thereby enhances the effect of PGI2 remains unclear. Previous studies have revealed that the drug inhibits the synthesis of TxB2 in platelets, an effect confirmed in the present study.`-Since PGI2, propranolol, and the combination of PGI2 and propranolol inhibited Tx synthesis to the same extent, it is unlikely that such a mechanism can explain the enhancement by propranolol of PGI2 inhibition of aggregation. The antiplatelet activity of propranolol has also been attributed to inhibition of calcium mobilization or utilization. 3 29-3' While the present study does not address this mechanism, it may possibly explain the observed results.
The data indicate that PGI2 inhibits the synthesis of Tx, and this inhibition appears to be mediated by cyclic AMP at higher concentrations. Other investigators have also found that cyclic AMP and agents that stimulate its synthesis will inhibit the synthesis of Tx by platelets. However, it is unclear whether the inhibition occurs at the level of phospholipase or cyclooxygenase. [32] [33] [34] We found that PGI2 inhibited both thrombinand arachidonic acid-stimulated Tx synthesis. This would suggest a site of inhibition distal to arachidonic acid or at cyclooxygenase. Vol. 17, No. 6, June 1985 In summary, propranolol treatment did not increase PGI2 synthesis by vascular endothelium. However, the combination of PGI2 and propranolol resulted in a greater than additive effect on inhibition of platelet aggregation in vitro. The inhibitory action of PGI2 on platelets appears to be mediated by cyclic AMP, whereas the attenuation of aggregation by propranolol is independent of cyclic AMP. Instead, propranolol appears to inhibit the synthesis and the actions of TxA2 'I The additive effect of these agents on aggregation is probably the result of their different mechanisms of action. Propranolol is a drug that is widely used in the treatment of angina pectoris. Recent evidence suggests that propranolol treatment may reduce mortality after a myocardial infarction.35 It is possible that some of the benefit of the drug under these conditions may be related to its direct inhibitory effects on platelet aggregation or its indirect enhancement of the antiplatelet activity of endogenously synthesized PGI2.
